12-WEEKS OF CHEMOTHERAPY AND INVOLVED FIELD RADIOTHERAPY (RT) ARE HIGHLY EFFECTIVE FOR UNFAVORABLE HODGKINS-DISEASE (HD) - THE STANFORD V REGIMEN

被引：0
|
作者：
BARLETT, NL [1 ]
ROSENBERG, SA [1 ]
HOPPE, RT [1 ]
HORNING, SJ [1 ]
机构：
[1] STANFORD UNIV,MED CTR,STANFORD,CA 94305
来源：
BLOOD | 1993年 / 82卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A333 / A333
页数：1
相关论文
共 26 条
  • [21] Minimal initial chemotherapy plus involved field radiotherapy (RT) versus mantle field RT for clinical stage IA/IIA supra-diaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 trial.
    Radford, J
    Williams, MV
    Hancock, BW
    Hoskin, P
    Sun-Mynt, H
    Smith, P
    Qian, W
    Linch, D
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [22] COMBINED MODALITY TREATMENT IN OVER 200 CHILDREN WITH HODGKINS-DISEASE - RISK-ADAPTED CHEMOTHERAPY, LOW-DOSE INVOLVED FIELD IRRADIATION AND SELECTIVE SPLENECTOMY - A REPORT OF THE COOPERATIVE THERAPY STUDY DAL-HD-82
    SCHELLONG, G
    BRAMSWIG, J
    LUDWIG, R
    GEREIN, V
    JOBKE, A
    JURGENS, H
    KABISCH, H
    STOLLMANN, B
    WEINEL, P
    GADNER, H
    SCHWARZE, EW
    WANNENMACHER, M
    KLINISCHE PADIATRIE, 1986, 198 (03): : 137 - 146
  • [23] Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma:: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group
    Engert, A
    Schiller, P
    Josting, A
    Herrmann, R
    Koch, P
    Sieber, M
    Boissevain, F
    de Wit, M
    Mezger, J
    Dühmke, E
    Willich, N
    Müller, RP
    Schmidt, BF
    Renner, H
    Müller-Hermelink, HK
    Pfistner, B
    Wolf, J
    Hasenclever, D
    Löffler, M
    Diehl, V
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3601 - 3608
  • [24] Treatment planning and delivery of involved field radiotherapy in advanced Hodgkin's disease: results from a questionnaire-based audit for the UK Stanford V regimen vs ABVD clinical trial quality assurance programme (ISRCTN 64141244)
    Diez, P.
    Hoskin, P. J.
    Aird, E. G. A.
    BRITISH JOURNAL OF RADIOLOGY, 2007, 80 (958): : 816 - 821
  • [25] High-risk Hodgkin's disease (HD):: ABVD chemotherapy (4 cycles) followed by BEAM-conditioned autologous stem cell transplantation (ASCT) and focal radiotherapy (RT) versus intensive chemotherapy (3 cycles) followed by involved field RT (IF-RT).: Two-year results of the GOELAMS H97-GM multicentric randomized trial.
    Escoffre-Barbe, M
    Hunault-Berger, M
    Desablens, B
    Le Prisé, PY
    Vigier, M
    Lacotte-Thierry, L
    Traullé, C
    Dugay, J
    Legouffe, E
    Lucas, V
    Ghandour, C
    Maigre, M
    Casassus, P
    Le Tortorec, S
    Maisonneuve, S
    Colombat, P
    Colonna, P
    Andrieu, JM
    BLOOD, 2000, 96 (11) : 791A - 791A
  • [26] Bulky Hodgkin's disease (S-HD) :: Treatment with an initial 7-drug chemotherapy (CT) delivered over 12 weeks followed by high-dose extended field irradiation (EF-RT), seven-year results of the goelams H90M multicentric randomized trial.
    Andrieu, JM
    Jais, JP
    Escoffre-Barbe, M
    Delwail, V
    Desablens, B
    Kiladjian, JJ
    Hunault, M
    Casassus, P
    Ghandour, C
    Le Prisé, PY
    Lejeune, F
    Simon, M
    Traullé, C
    Colonna, P
    BLOOD, 1999, 94 (10) : 528A - 528A
123